Replimune Group

NSQ:REPL · US76029N1063

BiotechnologySmall

360° View

Value6

Price/Sales29

Price/Earnings44

Price/Book1

Dividend Yield—

Growth11

Revenue Growth—

Profit Growth21

Capital Growth51

TSR 52w12

Safety6

Leverage20

Liquidity42

Refinancing21

Combined1

Sentiment47

Analyst Opinions1

Pro Holdings63

Opinion Changes65

Market Pulse66

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Founded2017

Employees403

Websitereplimune.com

ISINUS76029N1063

Last UpdateApr 2, 2026

Index & Theme

ImmunologyOncologyHealth CareMedicalTherapeutics

Description

Replimune Group, Inc. operates as a clinical-stage biotechnology company. The company engages in applying its leading expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through its novel oncolytic immunothera…

Analysis

Replimune Group's 360° View rank of 1 places it among the weakest overall — better than 1% of its true peers.

It's lagging on growth (11) and expensive versus peers (6). On safety it is highly leveraged (6), and the market shows muted sentiment (47). Taken together, its Combined rank of 1 reads as among the weakest overall.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Replimune Group with its peers

Savara

NSQ:SVRA

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Precision BioSciences

NAQ:DTIL

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Candel Therapeutics

NMQ:CADL

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Zentalis Pharmaceuticals

NMQ:ZNTL

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Tharimmune

NAQ:THAR

—

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Corvus Pharmaceuticals

NMQ:CRVS

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →